NCT00479492View on ClinicalTrials.gov

Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Obesity
Interventions
DRUG

CP-866,087

1 mg of CP-866,087, administered QD for 84 days

DRUG

CP-866,087

5 mg of CP-866,087, administered QD for 84 days

DRUG

CP-866,087

10 mg of CP-866,087, administered QD for 84 days

DRUG

placebo

placebo administered QD for 84 days

Trial Locations (4)

32809

Pfizer Investigational Site, Orlando

49007

Pfizer Investigational Site, Kalamazoo

78209

Pfizer Investigational Site, San Antonio

97239

Pfizer Investigational Site, Portland

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY